Payment overview · 2025
General Payments
$407.48
20 reported records · 12 companies
Healthcare provider profile · identity verified
Arthur E. Hale, MD
Allopathic & Osteopathic Physicians|Family Medicine · BRANSON, MO · NPI 1346330784
Verified facts
What the public records show
CMS Open Payments records show Arthur E. Hale, MD received $407.48 in general payments during 2025 across 20 reported records.
Lilly USA, LLC accounted for 20.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Fanapt, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 265 claims for Eliquis by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $84.43 | 20.7% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $52.46 | 12.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.43 | 12.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.96 | 9.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $35.40 | 8.7% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.73 | 6.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.42 | 6.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.43 | 5.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.13 | 4.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.87 | 4.9% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.02 | 4.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.20 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $407.48 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $54.49 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $52.46 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $35.40 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $27.73 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $26.18 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $13.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 36 | exact normalized | Medicare Part D |
| FANAPT fanapt |
2025 | Fanapt | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 97 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 125 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
81 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
66 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
125 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
36 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
265 | 66 |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 983 | 284 |
| Levothyroxine Sodium | Levothyroxine Sodium | 965 | 253 |
| Lisinopril | Lisinopril | 842 | 232 |
| Amlodipine Besylate | Amlodipine Besylate | 770 | 216 |
| Tramadol Hcl | Tramadol Hcl | 745 | 163 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 659 | 154 |
| Losartan Potassium | Losartan Potassium | 573 | 168 |
| Alprazolam | Alprazolam | 563 | 99 |
| Gabapentin | Gabapentin | 560 | 138 |
| Omeprazole | Omeprazole | 545 | 153 |
| Pantoprazole Sodium | Pantoprazole Sodium | 507 | 154 |
| Sertraline Hcl | Sertraline Hcl | 491 | 140 |
| Tamsulosin Hcl | Tamsulosin Hcl | 467 | 129 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 460 | 111 |
| Metformin Hcl | Metformin Hcl | 404 | 121 |
| Carvedilol | Carvedilol | 391 | 108 |
| Oxycodone Hcl | Oxycodone Hcl | 328 | 52 |
| Simvastatin | Simvastatin | 328 | 89 |
| Furosemide | Furosemide | 321 | 106 |
| Hydrochlorothiazide | Hydrochlorothiazide | 308 | 90 |
| Metoprolol Tartrate | Metoprolol Tartrate | 299 | 84 |
| Montelukast Sodium | Montelukast Sodium | 298 | 77 |
| Clonazepam | Clonazepam | 290 | 49 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 284 | 44 |
| Potassium Chloride | Potassium Chloride | 274 | 91 |
| Eliquis | Apixaban | 265 | 66 |
| Fluticasone Propionate | Fluticasone Propionate | 252 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 245 | 74 |
| Clopidogrel | Clopidogrel Bisulfate | 237 | 66 |
| Trazodone Hcl | Trazodone Hcl | 223 | 63 |
| Pregabalin | Pregabalin | 222 | 35 |
| Lorazepam | Lorazepam | 216 | 37 |
| Glimepiride | Glimepiride | 206 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 206 | 66 |
| Spironolactone | Spironolactone | 205 | 61 |
| Testosterone Cypionate | Testosterone Cypionate | 178 | 27 |
| Allopurinol | Allopurinol | 172 | 46 |
| Mirtazapine | Mirtazapine | 168 | 52 |
| Warfarin Sodium | Warfarin Sodium | 159 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 156 | 36 |
| Famotidine | Famotidine | 150 | 46 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 144 | 30 |
| Lovastatin | Lovastatin | 138 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 134 | 30 |
| Alendronate Sodium | Alendronate Sodium | 133 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 130 | 34 |
| Ropinirole Hcl | Ropinirole Hcl | 126 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 126 | 22 |
| Ozempic | Semaglutide | 125 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 29 |
| Finasteride | Finasteride | 121 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 120 | 32 |
| Atenolol | Atenolol | 115 | 37 |
| Meloxicam | Meloxicam | 115 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 108 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 105 | 32 |
| Morphine Sulfate Er | Morphine Sulfate | 105 | 16 |
| Buspirone Hcl | Buspirone Hcl | 104 | 23 |
| Prednisone | Prednisone | 104 | 59 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 98 | 29 |
| Jardiance | Empagliflozin | 97 | 29 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 94 | 28 |
| Metformin Hcl Er | Metformin Hcl | 93 | 28 |
| Glipizide | Glipizide | 89 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 86 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 25 |
| Symbicort | Budesonide/Formoterol Fumarate | 81 | 24 |
| Baclofen | Baclofen | 80 | 15 |
| Donepezil Hcl | Donepezil Hcl | 79 | 22 |
| Propranolol Hcl | Propranolol Hcl | 78 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 77 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 71 | 31 |
| Solifenacin Succinate | Solifenacin Succinate | 70 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | 18 |
| Trulicity | Dulaglutide | 66 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 65 | 20 |
| Fenofibrate | Fenofibrate | 64 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 64 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 16 |
| Ezetimibe | Ezetimibe | 63 | 15 |
| Aripiprazole | Aripiprazole | 62 | 11 |
| Ondansetron Odt | Ondansetron | 62 | 13 |
| Synthroid | Levothyroxine Sodium | 62 | 19 |
| Diazepam | Diazepam | 59 | 15 |
| Azelastine Hcl | Azelastine Hcl | 58 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 57 | suppressed |
| Xarelto | Rivaroxaban | 57 | 13 |
| Clonidine Hcl | Clonidine Hcl | 55 | 18 |
| Azithromycin | Azithromycin | 52 | 36 |
| Acyclovir | Acyclovir | 51 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 50 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 49 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 20 |
| Bupropion Xl | Bupropion Hcl | 48 | 15 |
| Estradiol | Estradiol | 48 | 12 |
| Topiramate | Topiramate | 48 | 13 |
| Lamotrigine | Lamotrigine | 46 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 46 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 45 | suppressed |
| Olanzapine | Olanzapine | 45 | 14 |
| Temazepam | Temazepam | 45 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 44 | suppressed |
| Nitroglycerin | Nitroglycerin | 43 | 21 |
| Nystatin | Nystatin | 43 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 32 |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Glipizide Er | Glipizide | 41 | suppressed |
| Carisoprodol | Carisoprodol | 40 | suppressed |
| Cephalexin | Cephalexin | 40 | 20 |
| Fentanyl | Fentanyl | 40 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 13 |
| Irbesartan | Irbesartan | 37 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 36 | 36 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 31 |
| Primidone | Primidone | 36 | suppressed |
| Ramipril | Ramipril | 36 | suppressed |
| Digoxin | Digoxin | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 33 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Linzess | Linaclotide | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | 13 |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Methadone Hcl | Methadone Hcl | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 12 |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Phenobarbital | Phenobarbital | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 20 |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 14 |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Levemir | Insulin Detemir | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Oxycontin | Oxycodone Hcl | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Epinephrine | Epinephrine | 17 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Dexilant | Dexlansoprazole | 14 | suppressed |
| Famciclovir | Famciclovir | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 13 |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Fanapt | Iloperidone | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $407.48 · 20 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, Auvelity, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, FANAPT, FREESTYLE LIBRE, JARDIANCE, KISUNLA, MOUNJARO, Ozempic, PREVNAR 20, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, Wegovy, YUPELRI | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error